FDA-approved small-molecule kinase inhibitors

Peng Wu, Thomas E. Nielsen, Mads Hartvig Clausen

Research output: Contribution to journalJournal articleResearchpeer-review

6574 Downloads (Pure)

Abstract

Kinases have emerged as one of the most intensivelypursued targets in current pharmacological research,especially for cancer, due to their critical roles in cellularsignaling. To date, the US FDA has approved 28 smallmoleculekinase inhibitors, half of which were approvedin the past 3 years. While the clinical data of theseapproved molecules are widely presented and structure–activity relationship (SAR) has been reported forindividual molecules, an updated review that analyzesall approved molecules and summarizes current achievementsand trends in the field has yet to be found. Herewe present all approved small-molecule kinase inhibitorswith an emphasis on binding mechanism and structuralfeatures, summarize current challenges, anddiscuss future directions in this field.
Original languageEnglish
JournalTrends in Pharmacological Sciences
Volume36
Issue number7
Pages (from-to)422-439
Number of pages18
ISSN0165-6147
DOIs
Publication statusPublished - 2015

Keywords

  • Cancer
  • Protein kinase
  • Lipid kinase
  • Tyrosine kinase
  • Serine/threonine kinase
  • Crystal structure

Fingerprint

Dive into the research topics of 'FDA-approved small-molecule kinase inhibitors'. Together they form a unique fingerprint.

Cite this